Drug A (Blinded Drug)

Phase 1

UUniversity of Maryland, Baltimore

Drug A (Blinded Drug) is one of 37 therapeutic programs targeting Opioid Use Disorder. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Opioid Use DisorderRecruiting

Opioid Use DisorderPhase 1

Recruiting

Competition

Competitive Landscape

116 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

2 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

5 4

Dayvigo

Eisai

Phase 2

2 5

Vraylar

AbbVie

Phase 2

1 6

Ozempic

Novo Nordisk

Phase 2

1 7

Mounjaro

Eli Lilly

Phase 2

1 8

Victoza

Novo Nordisk

Phase 2

1 9

Diamox

Teva

Phase 2

—10

Buprenorphine/naloxone

Astellas

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Opioid Use Disorder

NCT05829655

Clinical

Trials by Indication[1]

Opioid Use Disorder1 trial

Measuring Acute Drug Demand in Humans

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT05829655·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug A (Blinded Drug). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug A (Blinded Drug). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Maryland, Baltimore

Drug A (Blinded Drug)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Opioid Use Disorder1 trial

References

Drug Info

Quick Facts

Related News